
Claims

1. Use of a~~A~~ combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof:



I

in the manufacture of a medicament for the treatment of cancer.

2. The use ~~combination~~ according to claim 1, wherein the pharmaceutically acceptable salt of the compound of formula I is the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate or acetate salt.

3. The ~~combination~~ use according to claim 1 or claim 2, wherein the glucocorticoid is selected from the group consisting of dexamethasone, fluocinolone acetonide and prednisone.

4. The ~~combination~~ use according to claim 1 or claim 2, wherein the glucocorticoid is dexamethasone.

5. The ~~combination~~ use according to any one of claims 1 to 4, wherein the molar ratio of glucocorticoid to compound of formula I or a pharmaceutically acceptable salt thereof in said combination is from 1:500 to 500:1.

~~6. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a combination according to any one of claims 1 to 5.~~

~~7. A kit comprising a combination according to any one of claims 1 to 6, and optionally, instructions for treating a patient.~~

~~8. The use of the combination according to any one of claims 1 to 5, composition according to claim 6 or kit according to claim 7, in the manufacture of a medicament for the treatment of cancer.~~

6~~9~~. The use ~~use of a combination, composition or kit for use~~ according to any preceding claim~~claim 8~~, wherein said cancer is selected from a hematologic cancer and breast cancer.

7~~10~~. The use of ~~a combination, composition or kit for use~~ according to claim 6~~9~~, wherein said hematologic cancer is selected from multiple myeloma, lymphoma and leukemia; or wherein said breast cancer is a triple negative breast cancer.


8~~11~~. The use ~~of a combination, composition or kit~~ according to any ~~one of claims 8 to 10~~ preceding claim wherein said cancer is relapsed and/or refractory.

9~~12~~. The use ~~of a combination, composition or kit for use~~ according to any ~~one of claims 8 to 11~~preceding claim, wherein the glucocorticoid and the compound of formula I or a pharmaceutically acceptable salt thereof are to be administered concurrently, sequentially or separately.

10~~3~~. The use ~~of a combination, composition or kit for use~~ according to any ~~one of claims 8 to 12~~preceding claim, wherein ~~in said treatment~~ the glucocorticoid is to be administered at a dosage range of from 0.1 to 1 mg/kg body weight patient.

11~~4~~. The use ~~of a combination, composition or kit for use~~ according to claim 10~~,3~~ wherein ~~in said treatment~~ the glucocorticoid is to be administered at a dosage range of from 0.3 to 0.5 mg/kg body weight patient.


12. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof:



I

13. A kit comprising a pharmaceutical composition according to claim 6, and optionally, instructions for treating a patient.


14~~5~~. Use of a compound of formula I or a pharmaceutically acceptable salt thereof:



I,

in the manufacture of a medicament for the treatment of cancer, wherein the compound of formula I or a pharmaceutically acceptable salt thereof is to be administered in combination with a glucocorticoid.

15~~6~~. Use of a glucocorticoid in the manufacture of a medicament for the treatment of cancer, wherein ~~the~~ a proteasome inhibitor is to be administered in combination with a compound of formula I or a pharmaceutically acceptable salt thereof:



I.